<DOC>
	<DOCNO>NCT01024283</DOCNO>
	<brief_summary>The principal research objective additional research protocol support collection , storage use tumour surrogate ( peripheral blood mononuclear cell - PBMNCs ) . The objective study perform assay study pharmacodynamic ( PD ) marker confirm target modulation .</brief_summary>
	<brief_title>Analysis Pharmacodynamic Changes With AUY922A , HSP90 Inhibitor</brief_title>
	<detailed_description>Study objectives - 1 . Evaluation HSP70 , p-ERK , ERK , p-AKT AKT peripheral blood mononuclear cell ( PBMNC ) . Evaluation p-AKT AKT do commercially available Meso Scale Discovery ( MSD ) enzyme link immunosorbent assay ( ELISA ) kit , HSP70 study use ELISA technique develop within Institute Cancer Research . 2 . Evaluation HSP70 , p-AKT , AKT , p-ERK , ERK , HER-2 p-HER2 tumour tissue . Evaluation p-AKT , AKT , p-ERK , ERK , HER-2 p-HER2 do commercially available MSD ELISA kit , HSP70 study use ELISA technique develop within Institute Cancer Research . Study design - All patient enter open label , phase I dose escalation phase II expansion arm AUY922A Royal Marsden Hospital ask participate study . Patients attend additional appointment study sample take visit plan Phase I/II clinical trial . Consent donate sample research study voluntary patient ask sign separate consent form .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>All patient enter open label phase I dose escalation phase II expansion arm AUY922A Royal Marsden Hospital ask participate study . Patients attend additional appointment study sample take visit plan phase I/II clinical trial . Consent donate sample research study voluntary patient ask sign separate consent form . Any patient enter open label phase I dose escalation phase II expansion arm AUY922A ask participate . Patients advance cancer safely biopsiable eligible participate . Patients know coagulation disorder .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Heat Shock Protein 90 Inhibitor ( HSP90 )</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Blood</keyword>
	<keyword>Biopsy</keyword>
	<keyword>Solid malignancy</keyword>
</DOC>